Autres langues Enliven Therapeutics, Inc.

Actions

ELVN

US29337E1029

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
23,04 ^USD	-3,23%		-1,66%	+66,47%

14/05	Enliven Therapeutics réduit sa perte au premier trimestre	MT
11/04	Enliven Therapeutics, Inc. annonce des résultats positifs de l'essai clinique de phase 1 sur ELVN-001 dans le traitement de la leucémie myéloïde chronique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Enliven Therapeutics Q1 Loss Narrows	14/05
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update	14/05
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11/04
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11/04
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors	09/04
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors	09/04
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding	03/04
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024	28/03
North American Morning Briefing : Investors -2-	21/03
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates	19/03
Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding	19/03
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	14/03
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	27/02
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to NASDAQ Biotechnology Index	18/12
Enliven Therapeutics Q3 Loss Narrows	09/11
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update	09/11
Enliven Therapeutics Insider Sold Shares Worth $104,999, According to a Recent SEC Filing	06/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Enliven Therapeutics, Inc.

Actions

ELVN

US29337E1029

Autres langues

Filtres